Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Publications IgAN

Long-Term Outcomes in IgA Nephropathy

View
Publications IgAN

Efficacy and Safety of Sparsentan Versus Irbesartan in Patients with IgA Nephopathy (PROTECT): 2-year Results From a Randomised Active-Controlled Phase 3 Trial

View
Publications FSGS

Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety

View
Publications FSGS

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

View
Publications IgAN

Kidney Failure Events, Cardiovascular Disease Events, and All-Cause Mortality in Immunoglobulin A Nephropathy Patients in a Real-World Database

View
Publications IgAN

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

View
Publications IgAN

Clinicopathological Characteristics of Adult IgA Nephropathy in the United States

View
Publications Cystinuria

Assessment of health‐related quality of life in patients with cystinuria on tiopronin therapy

View
Publications IgAN

Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)

View
Publications FSGS

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS

View